enzymes

  • Bio
    Chinese scientists CRISPR a human for the first time

    Chinese scientists CRISPR a human for the first time

    A group of Chinese scientists injected a human being with cells genetically edited using CRISPR-Cas9 technology. This is the first time CRISPR has been used on a fully formed adult human and it’s encouraged a biomedical battle between China and the United States. The scientists from China are hoping the genetically edited cells will help their patient fend off a virulent type of… Read More

  • Bio
    Oral arguments for who owns CRISPR-Cas9 start next month

    Oral arguments for who owns CRISPR-Cas9 start next month

    The date has been set for oral arguments to begin over who owns the patent rights to the gene-editing wonder CRISPR-Cas9. Berkeley’s Jennifer Doudna and her colleague from the Max Planck Institute Emmanuelle Charpentier head to court on December 6th to face off against MIT’s Feng Zhang and present their argument before three US Patent and Trademark Office judges on why… Read More

  • Bio
    CRISPR loses Nobel to tiny machines

    CRISPR loses Nobel to tiny machines

    CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauvage, J. Fraser Stoddart, and Bernard L. Feringa – three men who developed the world’s smallest machines using molecular physics. Each will share equally in the 8 million Swedish kronor… Read More

  • Bio
    Jennifer Doudna, inventor of gene editing technology CRISPR Cas9, is coming to Disrupt

    Jennifer Doudna, inventor of gene editing technology CRISPR Cas9, is coming to Disrupt

    Berkeley professor of chemistry and molecular and cell biology and the inventor of the revolutionary CRISPR Cas9 gene editing technology Jennifer Doudna is going to join us for the first time on our Disrupt stage in SF this September. We’ll chat with Doudna about her discovery of a tool called Cas9 that not only is upending the biotech industry but could have a domino effect on… Read More

  • Bio
    A federal safety board just OK’d the first CRISPR trial to genetically alter humans

    A federal safety board just OK’d the first CRISPR trial to genetically alter humans

    In the spring of 2015, a group of Chinese scientists modified the DNA of 54 embryos using CRISPR/Cas 9 technology. Twenty-eight of those embryos were successful, but 26 — nearly half of them — failed, setting off a heated debate throughout the scientific community on the ethics of altering human genes. Regulators don’t currently allow the use of CRISPR on human DNA in the… Read More

  • BP Buys Verenium's Biofuel Business For $98 Million

    As oil continues to spill in the Gulf of Mexico, BP is looking towards alternatives such as biofuels. BP announced today that it will acquire the cellulosic biofuels business of Verenium. The $98.3 million deal includes Verenium’s biofuel facilities in Jennings, LA and San Diego, CA. But it doesn’t include Verenium’s commercial enzyme business, and allows Verenium to develop… Read More